A Phase 4 interventional study of Enstilar 0.005%-0.064% Topical Foam in Psoriasis, sponsored by Psoriasis Treatment Center of Central New Jersey. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-04.
Sponsored by Psoriasis Treatment Center of Central New Jersey · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey — 5 open to participants now, 5 under way, none of them phase 3. Psoriasis · Psoriasis Treatment Center of Central New Jersey.
Among the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2019, is one of 11 in phase 4, and was the 7th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →5 of the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey are open now, in 1 country. Recruiting first, the newest first:
Psoriasis Treatment Center of Central New Jersey · Sites in United States
Ages 18+
Psoriasis Treatment Center of Central New Jersey · Sites in United States
Ages 18+
Psoriasis Treatment Center of Central New Jersey · Sites in United States
Ages 18+
Psoriasis Treatment Center of Central New Jersey · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 27 across the 12 interventional studies, 3 across the 1 observational. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Psoriasis Treatment Center of Central New Jersey is the lead sponsor of 17 studies on the registry; 6 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Psoriasis by Psoriasis Treatment Center of Central New Jersey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
Drug: Enstilar 0.005%-0.064% Topical Foam
Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
PGA x BSA improvement
body surface area multiplied by physician global assessment
Time frame: 16 weeks
BSA improvement
body surface area improvement
Time frame: 16 weeks
Dermatology Life Quality Index improvement
patient reported outcome improvements of DLQI (Dermatology Life Quality Index). Calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percentage of the maximum possible score of 30.
Time frame: 16 weeks
Itch Numerical Rating Scale
Patient reported itch scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: 16 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2019 (actual). Primary completion is estimated for Sep 2019, 7 months after the start.
Of 75 non-industry phase 4 interventional studies under Psoriasis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 7 months is below that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Psoriasis Treatment Center of Central New Jersey